Effect of SGLT2 inhibitors on anemia and their possible clinical implications.
Anemia
Chronic kidney disease
Diabetes
Enfermedad renal crónica
Heart failure
Inhibidores de SGLT2
Insuficiencia cardíaca
SGLT2 inhibitors
Journal
Nefrologia
ISSN: 2013-2514
Titre abrégé: Nefrologia (Engl Ed)
Pays: Spain
ID NLM: 101778581
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
01
08
2023
accepted:
11
11
2023
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
11
4
2024
Statut:
aheadofprint
Résumé
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was early appearent that these drugs increased erythropoietin levels and erythropoiesis, and improved iron metabolism. Mediation studies found that the increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs. In this review, we discuss the mechanisms for improving erythropoiesis and the implication of the increase in hemoglobin on the cardiorenal prognostic benefit of these drugs.
Identifiants
pubmed: 38604895
pii: S2013-2514(24)00069-5
doi: 10.1016/j.nefroe.2024.03.011
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024. Published by Elsevier España, S.L.U.